SCHEMBL30656333

SCHEMBL30656333

COC(=O)c1c(C)sc2ccc(O)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.49
TDP1 Q9NUW8 1/20 0.49
CA12 O43570 4/20 0.49
CA1 P00915 4/20 0.49
CA2 P00918 4/20 0.49
CA7 P43166 4/20 0.49
CA9 Q16790 4/20 0.49
CA14 Q9ULX7 4/20 0.49
PDK2 Q15119 1/20 0.49
PDK4 Q16654 1/20 0.49
CYP3A4 P08684 3/20 0.47
ACHE P22303 1/20 0.47
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 4/20 0.45
PKM P14618 3/20 0.45
HPGD P15428 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ALOX15 P16050 2/20 0.45
HSD17B10 Q99714 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26661117 1.00 L3MBTL1 (0.49) L3MBTL1TDP1CA12CA1CA2
SCHEMBL5241179 0.89 ESR1 (0.48) L3MBTL1CA12CA1CA2CA7
SCHEMBL26661126 0.84 L3MBTL1 (0.68) L3MBTL1TDP1CYP3A4MAPK1LMNA
SCHEMBL30656314 0.84 L3MBTL1 (0.68) L3MBTL1TDP1CYP3A4MAPK1LMNA
SCHEMBL26661112 0.83 GAA (0.43) TDP1CA12CA1CA2CA7
SCHEMBL31351339 0.80 L3MBTL1 (0.46) L3MBTL1TDP1CA12CA1CA2
SCHEMBL26661109 0.80 L3MBTL1 (0.46) L3MBTL1TDP1CA12CA1CA2
SCHEMBL3599532 0.80 LMNA (0.71) L3MBTL1TDP1CA12CA1CA2
SCHEMBL9756981 0.79 MAPK1 (0.53) L3MBTL1TDP1CA12CA1CA2
SCHEMBL10953592 0.75 LMNA (0.41) L3MBTL1TDP1CA2CYP3A4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-11-13 US disclosed
EP-4532013-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-04-09 EP disclosed
CN-119421879-A Novel derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-02-11 CN disclosed
WO-2023227697-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346569-A1 NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM4, TRPM2, TRPM6 L3MBTL1 3962/4885TDP1 3429/4885CA12 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.